Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical features and outcomes of myelofibrosis patients with MPL mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

VNValentina NardiAKAndrew Kuykendall

Discussion

Loading...

Member takes

Overview

Retrospective case series shows high prevalence of HMR mutations in myelofibrosis, indicating risks for acute myeloid leukemia.

Key Points

  • Acute myeloid leukemia progression occurred in 15% of MPL-mutated myelofibrosis patients, highlighting serious risks.
  • Ruxolitinib was administered to 31 patients, while anemia-directed therapies included Danazol in 9 cases.
  • Retrospective case series involved 73 patients, confirming associations with myelofibrosis and MPL mutations.
  • Findings emphasize the need for improved risk stratification for myelofibrosis patients harboring MPL mutations.

Cite This Study

Nardi et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df7ahttps://doi.org/10.1182/blood-2025-5601
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations2025
  2. 2Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation2025
  3. 3MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”2025 · 2 citations
  4. 4Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.2025
  5. 5Mutational architecture and clonal heterogeneity in myelofibrosis: Prognostic role of variant type and acquisition sequence2025